FONT-SIZE Plus   Neg

AVEO, Astellas Say Tivozanib Superior To Sorafenib In Advanced RCC - Quick Facts

AVEO Pharmaceuticals, Inc. (AVEO) and Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) Tuesday said that tivozanib Phase 3 clinical trial demonstrated superiority over sorafenib in the primary endpoint of progression-free survival in patients with advanced renal cell carcinoma.

TIVO-1, a global, randomized Phase 3 clinical trial evaluated the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma. TIVO-1 is the first registration study in first-line renal cell carcinoma that is comparing an investigational agent against an approved VEGF therapy.

The companies noted that tivozanib demonstrated a well-tolerated safety profile consistent with the Phase 2 experience; the most commonly reported side effect was hypertension, a well established on-target and manageable effect of VEGFR inhibitors

Based on these data, AVEO and Astellas currently plan to submit for marketing approval of tivozanib in the US and Europe in 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After nearly a 2-year hiatus following its announcement that it is testing unmanned drones, Amazon finally offered a glimpse into the prototype and its functioning. It remains to be see if the company can work around regulatory hurdles to make it a reality. Microsoft's (MSFT) office assistant Cortana for iOS beta has arrived, but only 2000 people will be able to test the virtual assistant. Apple confirmed that it has bought face animation software firm Faceshift, although it was tight lipped about how it intends to use the new addition. The move is speculated as a bid to expand into virtual reality.
comments powered by Disqus
Follow RTT